CTD Announces Home-Based Dosing of First Patient in US Extension Protocol of Clinical Trial using Intravenous Administration of Trappsol (R) Cyclo (TM) for Niemann-Pick Disease Type C

Press/Media: Press / Media

PeriodMay 23 2019 → May 24 2019

Media coverage

5

Media coverage

  • TitleCTD Announces Home-Based Dosing of First Patient in US Extension Protocol of Clinical Trial using Intravenous Administration of Trappsol (R) Cyclo (TM) for Niemann-Pick Disease Type C
    Media name/outletPlus Company Updates (PCU)
    CountryUnited States
    Date5/24/19
    PersonsDarius Adams
  • TitleCTD Announces Home-Based Dosing of First Patient in US Extension Protocol of Clinical Trial using Intravenous Administration of Trappsol (R) Cyclo (TM) for Niemann-Pick Disease Type C
    Media name/outletYahoo! Finance
    CountryUnited States
    Date5/23/19
    PersonsDarius Adams
  • TitleCTD Announces Home-Based Dosing of First Patient in US Extension Protocol of Clinical Trial using Intravenous Administration of Trappsol (R) Cyclo (TM) for Niemann-Pick Disease Type C
    Media name/outletGlobal English (Middle East and North Africa Financial Network)
    CountryJordan
    Date5/23/19
    PersonsDarius Adams
  • TitleCTD Announces Home-Based Dosing of First Patient in US Extension Protocol of Clinical Trial using Intravenous Administration of Trappsol (R) Cyclo (TM) for Niemann-Pick Disease Type C
    Media name/outletMorningstar.com
    CountryUnited States
    Date5/23/19
    PersonsDarius Adams
  • TitleCTD Announces Home-Based Dosing of First Patient in US Extension Protocol of Clinical Trial using Intravenous Administration of Trappsol (R) Cyclo (TM) for Niemann-Pick Disease Type C
    Media name/outletFSCwire
    CountryCanada
    Date5/23/19
    PersonsDarius Adams